重组人干扰素α1b治疗小儿支气管炎的临床疗效

Clinical Efficacy of Aerosol Inhalation of Recombinant Human Interferon α1b in Children With Bronchitis

目的探讨重组人干扰素α1b雾化吸入治疗小儿支气管炎临床疗效。方法选择2017年1—8月在我院诊断治疗的小儿支气管肺炎患儿80例为研究对象,随机分为研究组与对照组各40例。两组均给予控制感染、止咳、平喘等常规治疗。研究组在此治疗基础上给予重组人干扰素α1b雾化吸入治疗。比较两组临床疗效以及肺部啰音消失时间,喘憋消失时间,咳嗽消失时间,体温恢复正常时间。结果研究组总有效率高于对照组,差异有统计学意义(P<0.05)。研究组肺部啰音、喘憋、咳嗽消失时间以及体温恢复正常时间短于对照组,差异有统计学意义(P<0.05)。结论小儿支原体炎采用重组人干扰素α1b雾化吸入能显著提高临床疗效,促进恢复。

Objective To discuss the clinical efficacy of aerosol inhalation of recombinant human interferonα1b in children with bronchitis.Methods 80 cases with bronchitis from January to August 2017 were selected and were randomly divided into the study group and the control group,each of 40 cases.The two groups were given conventional treatment such as infection control,cough relieving and antiasthmatic treatment.The study group was treated with aerosol inhalation of recombinant human interferonα1b on the basis of this treatment.The clinical efficacy,the time of pulmonary rales disappearance,the time of wheezing and disappearing,the time of cough disappear,and the time when the body temperature returned to normal were compared between the two groups.Results The total effective rate of the study group was significantly higher than that of the control group,the difference was statistically significant(P<0.05).The time of pulmonary rales disappearance,the time of wheezing and disappearing,the time of cough disappear,and the time when the body temperature returned to normal in the study group were shorter than those in the control group,the difference was statistically significant(P<0.05).Conclusion Nebulized inhalation of recombinant human interferonα1b in children with bronchitis can significantly improve the clinical efficacy and promote recovery.